Comments on "Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study"

Arthritis Rheumatol. 2025 Jan 19. doi: 10.1002/art.43117. Online ahead of print.
No abstract available

Publication types

  • Letter